Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily, Mid-Day, 11/9/11, unchartered water for the world economy and market

The 6 W’s: Who, what, where, when, why and what of it …

 

While stocks moved sharply higher at the start of trading on Thursday, buying interest … waned after the open.

The RegMed universe has been pulling back based on visibility. Currently, incremental highs are few and far between yet a few are in positive territory, although the NASDAQ is only just above the unchanged line.  The initial strength on Wall Street was partly due to easing concerns about the financial situation in the EU. 

 

Mid-Day: The NASDAQ +5.65 (+0.27%) to 2,627.30. The Dow is UP +118.84 (+1.01%) to 11,899.84.

 

Mid-Day Movers: Athersys (NASDAQ:ATHX), Brainstorm (OTC BB: BCLI), BioMimetic (NASDAQ:BMTI), BioTime (AMEX: BTX),  Cytori (NASDAQ:CYTX), Dendreon (NASDAQ:DNDN), Fibrocell (OTC BB: FCSC), Geron (Gern), ImmunoCellular (OTC BB: IMUC),  International Stem Cell (OTC BB: ISCO), Opexa(OPXA), Pluristem (NASDAQ:PSTI), ReNeuron (RENE.LON) and ThermoGenesis (kool).  

 

What’s new in the regenerative medicine/stem cell market …

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), provided a review of recent accomplishments for shareholders and investors. http://finance.yahoo.com/news/BrainStorm-Cell-Therapeutics-bw-973255927.html?x=0&l=1

International Stem Cell Corporation (OTC BB: ISCO) Launches of 2 New Sales Initiatives for Lifeline Skin Care:  The 1st is the successful conclusion of an agreement in principle to distribute its Lifeline Skin Care product line in the UAE via a strategic relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD of Los Angeles and Santa Barbara, CA. The 2nd is the engagement of Dr. K. McIsaac who will distribute Lifeline’s products in Australia and New Zealand under Lifeline’s own brand name.

Mesoblast Limited (ASX: MSB) Reports Positive Results Using Intravenously Injected Adult Stem Cells for Type 2 Diabetes:  a single intravenous injection of its proprietary adult stem cells resulted in significant lowering of blood sugar levels for up to 8 weeks in a controlled, randomized preclinical trial in non-human primates with Type 2 diabetes. This was accompanied by significant reductions in circulating inflammatory markers to levels associated with protection against heart attacks and death in patients with Type 2 diabetes.